Literature DB >> 17102709

A comparative meta-analysis of Clinical Global Impressions change in antidepressant trials.

Glen I Spielmans1, Joseph P McFall.   

Abstract

Two scales of the Clinical Global Impressions (CGI) Scale are frequently used in antidepressant trials. No research has systematically addressed how CGI change compares to change on established measures such as the Hamilton Depression Rating Scale (HAM-D), Montgomery-Asberg Depression Rating Scale, or Beck Depression Inventory. The current meta-analysis examined 75 antidepressant trials in which the CGI was used along with at least one other popular depression measure. The CGI-Severity scale was significantly more conservative than the HAM-D in rating change in double-blind trials, but not in open trials. The Beck Depression Inventory was significantly more conservative than the CGI-Severity. The CGI-Improvement scale was significantly more liberal than the HAM-D or Montgomery-Asberg Depression Rating Scale. Rater bias or scale content may explain differences between measures. Given the often substantial differences between instruments, researchers should use a variety of measures rather than relying on any single tool in assessing treatment response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17102709     DOI: 10.1097/01.nmd.0000244554.91259.27

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  12 in total

1.  The clinical global impressions scale: applying a research tool in clinical practice.

Authors:  Joan Busner; Steven D Targum
Journal:  Psychiatry (Edgmont)       Date:  2007-07

2.  Minimal Clinically Important Differences (MCID) in Assessing Outcomes of Post-Traumatic Stress Disorder.

Authors:  Elina A Stefanovics; Robert A Rosenheck; Karen M Jones; Grant Huang; John H Krystal
Journal:  Psychiatr Q       Date:  2018-03

3.  Defining treatment response in trichotillomania: a signal detection analysis.

Authors:  David C Houghton; Matthew R Capriotti; Alessandro S De Nadai; Scott N Compton; Michael P Twohig; Angela M Neal-Barnett; Stephen M Saunders; Martin E Franklin; Douglas W Woods
Journal:  J Anxiety Disord       Date:  2015-09-24

4.  Reward-related brain function as a predictor of treatment response in adolescents with major depressive disorder.

Authors:  Erika E Forbes; Thomas M Olino; Neal D Ryan; Boris Birmaher; David Axelson; Donna L Moyles; Ronald E Dahl
Journal:  Cogn Affect Behav Neurosci       Date:  2010-03       Impact factor: 3.282

5.  Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data.

Authors:  William V Bobo; Gabriela C Angleró; Gregory Jenkins; Daniel K Hall-Flavin; Richard Weinshilboum; Joanna M Biernacka
Journal:  Hum Psychopharmacol       Date:  2016-03-21       Impact factor: 1.672

Review 6.  The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research.

Authors:  Patrick E McKnight; Todd B Kashdan
Journal:  Clin Psychol Rev       Date:  2009-02-07

7.  Investigating Habituation to Premonitory Urges in Behavior Therapy for Tic Disorders.

Authors:  David C Houghton; Matthew R Capriotti; Lawrence D Scahill; Sabine Wilhelm; Alan L Peterson; John T Walkup; John Piacentini; Douglas W Woods
Journal:  Behav Ther       Date:  2017-08-10

8.  Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings.

Authors:  Boadie W Dunlop; Jaclyn Gray; Mark H Rapaport
Journal:  Behav Sci (Basel)       Date:  2017-06-27

9.  Long-term efficacy and safety of lamotrigine for all types of bipolar disorder.

Authors:  Yoshinori Watanabe; Seiji Hongo
Journal:  Neuropsychiatr Dis Treat       Date:  2017-03-20       Impact factor: 2.570

10.  A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.

Authors:  Helen Heussler; Jonathan Cohen; Natalie Silove; Nancy Tich; Marcel O Bonn-Miller; Wei Du; Carol O'Neill; Terri Sebree
Journal:  J Neurodev Disord       Date:  2019-08-02       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.